Healthcare / BiotechnologySwiss
$15.80
+0.34 (+2.13%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-34.8M · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$230M
P/E
N/A
•EV/EBITDA
N/A
•ROE
416.7%
↑Gross Margin
19.7%
↓Debt/Equity
-4.14
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+117.8%
FCF CAGR
—
FCF margin
-45.1%
FCF / Net income
0.71x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $77.2M · net income $-49.2M · FCF $-34.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $77.2M | $77.2M | $39.1M | $103.4M | $7.5M |
| Net Income | $-49.2M | $-49.2M | $-42.0M | $54.8M | $-71.1M |
| EBITDA | $-31.8M | $-31.8M | $-28.2M | $79.2M | $-40.6M |
| EPS | -3.78 | -3.78 | -3.69 | 5.01 | -11.67 |
| Gross Margin | 19.7% | 19.7% | 60.3% | 96.9% | 51.9% |
| Operating Margin | -48.7% | -48.7% | -84.7% | 49.5% | -695.5% |
| Net Margin | -63.8% | -63.8% | -107.3% | 53.0% | -951.1% |
| Balance Sheet | |||||
| Debt/Equity | -4.14 | -4.14 | 1.47 | 0.36 | -1.02 |
| Current Ratio | 1.29 | 1.29 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-34.8M | $-34.8M | $-35.7M | $23.5M | $-33.8M |
| Returns | |||||
| ROE | 416.7% | 416.7% | -151.5% | 91.4% | 162.7% |
| Valuation | |||||
| P/E | — | — | — | 1.83 | — |
| EV/EBITDA | — | — | — | 1.16 | — |
| P/B | — | — | 5.94 | 1.67 | — |
| Growth & Yield | |||||
| Revenue Growth | 97.3% | 97.3% | -62.2% | 1283.8% | — |
| EPS Growth | -2.4% | -2.4% | -173.7% | 142.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+32.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.69 → -3.78
Residual
+32.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.